The overproduction of catecholamines in pheochromocytoma/paraganglioma (PPGL) induces a hypermetabolic state. The aim of this study was to evaluate the incidence of a hypermetabolic state and differences in substrate metabolism in consecutive PPGL patients divided by catecholamine phenotype. Resting energy expenditure (REE) and respiratory quotient (RQ) were measured in 108 consecutive PPGL patients and 70 controls by indirect calorimetry. Hypermetabolic state was defined according to the Mifflin St. Jeor Equation as a ratio above 110%. Hypermetabolic state was confirmed in 70% of PPGL patients, regardless of phenotype. Older age, prevalence of diabetes mellitus and arterial hypertension were correlated with hypermetabolic PPGL as compared to normometabolic form. Analysis according to overproduced catecholamine showed differences in VCO2 (p < 0.05) and RQ (p < 0.01) and thus different substate metabolism between phenotypes in hypermetabolic form of PPGL. Lipid utilization was higher in the adrenergic phenotype (p = 0.001) and positively associated with the percentage of REE ratio (R = 0.48, p < 0.001), whereas the noradrenergic phenotype preferentially oxidizes carbohydrates (P = 0.001) and is correlated with the percentage of REE ratio (R = 0.60, p < 0.001). Hypermetabolic state in PPGL is a common finding in both catecholamine phenotypes. Hypermetabolic PPGL patients are older and suffer more from diabetes mellitus and arterial hypertension. Under basal conditions, the noradrenergic type preferentially metabolizes carbohydrates, whereas the adrenergic phenotype preferentially metabolizes lipids.

1st Department of Surgery 1st Faculty of Medicine and General Faculty Hospital Charles University 12800 Prague Czech Republic

3rd Department of Medicine 1st Faculty of Medicine and General Faculty Hospital Charles University 12800 Prague Czech Republic

Department of Urology 1st Faculty of Medicine and General Faculty Hospital Charles University 12800 Prague Czech Republic

Institute of Sport Medicine 1st Faculty of Medicine and General Faculty Hospital Charles University 12800 Prague Czech Republic

Zobrazit více v PubMed

Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–675. doi: 10.1016/S0140-6736(05)67139-5. PubMed DOI

Pacak K., Tella S. Pheochromocytoma and paraganglioma. In: Feingold K.R., Anawalt B., Boyce A., Chrousos G., Dungan K., Grossman A., Hershman J.M., Kaltsas G., Koch C., Kopp P., et al., editors. Endotext. South MDText.com, Inc.; Dartmouth, MA, USA: 2018. [(accessed on 1 June 2022)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK481899/

Petrak O., Haluzikova D., Kavalkova P., Strauch B., Rosa J., Holaj R., Brabcova Vrankova A., Michalsky D., Haluzik M., Zelinka T., et al. Changes in energy metabolism in pheochromocytoma. J. Clin. Endocrinol. Metab. 2013;98:1651–1658. doi: 10.1210/jc.2012-3625. PubMed DOI

Erlic Z., Beuschlein F. Metabolic Alterations in Patients with Pheochromocytoma. Exp. Clin. Endocrinol. Diabetes. 2019;127:129–136. doi: 10.1055/a-0649-0960. PubMed DOI

Barth E., Albuszies G., Baumgart K., Matejovic M., Wachter U., Vogt J., Radermacher P., Calzia E. Glucose metabolism and catecholamines. Crit. Care Med. 2007;35:S508–S518. doi: 10.1097/01.CCM.0000278047.06965.20. PubMed DOI

Gjedsted J., Buhl M., Nielsen S., Schmitz O., Vestergaard E.T., Tonnesen E., Moller N. Effects of adrenaline on lactate, glucose, lipid and protein metabolism in the placebo controlled bilaterally perfused human leg. Acta Physiol. 2011;202:641–648. doi: 10.1111/j.1748-1716.2011.02316.x. PubMed DOI

De Glisezinski I., Larrouy D., Bajzova M., Koppo K., Polak J., Berlan M., Bulow J., Langin D., Marques M.A., Crampes F., et al. Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue. J. Physiol. 2009;587:3393–3404. doi: 10.1113/jphysiol.2009.168906. PubMed DOI PMC

Petrák O., Rosa J., Holaj R., Štrauch B., Krátká Z., Kvasnička J., Klímová J., Waldauf P., Hamplová B., Markvartová A., et al. Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. J. Clin. Endocrinol. Metab. 2019;104:5170–5180. doi: 10.1210/jc.2018-02644. PubMed DOI

Eisenhofer G., Lenders J.W., Goldstein D.S., Mannelli M., Csako G., Walther M.M., Brouwers F.M., Pacak K. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin. Chem. 2005;51:735–744. doi: 10.1373/clinchem.2004.045484. PubMed DOI

Eisenhofer G., Timmers H.J., Lenders J.W., Bornstein S.R., Tiebel O., Mannelli M., King K.S., Vocke C.D., Linehan W.M., Bratslavsky G., et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J. Clin. Endocrinol. Metab. 2011;96:375–384. doi: 10.1210/jc.2010-1588. PubMed DOI PMC

Bechmann N., Eisenhofer G. Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma? Exp. Clin. Endocrinol. Diabetes. 2022;130:282–289. doi: 10.1055/a-1526-5263. PubMed DOI

Hartmann C., Radermacher P., Wepler M., Nussbaum B. Non-Hemodynamic Effects of Catecholamines. Shock. 2017;48:390–400. doi: 10.1097/SHK.0000000000000879. PubMed DOI

Batisse-Lignier M., Pereira B., Motreff P., Pierrard R., Burnot C., Vorilhon C., Maqdasy S., Roche B., Desbiez F., Clerfond G., et al. Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review. Medicine. 2015;94:e2198. doi: 10.1097/MD.0000000000002198. PubMed DOI PMC

Klímová J., Mráz M., Kratochvílová H., Lacinová Z., Novák K., Michalský D., Kvasnička J., Holaj R., Haluzíková D., Doležalová R.P., et al. Gene Profile of Adipose Tissue of Patients with Pheochromocytoma/Paraganglioma. Biomedicines. 2022;10:586. doi: 10.3390/biomedicines10030586. PubMed DOI PMC

Petrak O., Klimova J., Mraz M., Haluzikova D., Dolezalova R.P., Kratochvilova H., Lacinova Z., Novak K., Michalsky D., Waldauf P., et al. Pheochromocytoma With Adrenergic Biochemical Phenotype Shows Decreased GLP-1 Secretion and Impaired Glucose Tolerance. J. Clin. Endocrinol. Metab. 2020;105:1878–1887. doi: 10.1210/clinem/dgaa154. PubMed DOI

Mifflin M.D., St Jeor S.T., Hill L.A., Scott B.J., Daugherty S.A., Koh Y.O. A new predictive equation for resting energy expenditure in healthy individuals. Am. J. Clin. Nutr. 1990;51:241–247. doi: 10.1093/ajcn/51.2.241. PubMed DOI

Westenskow D.R., Schipke C.A., Raymond J.L., Saffle J.R., Becker J.M., Young E.W., Cutler C.A. Calculation of metabolic expenditure and substrate utilization from gas exchange measurements. JPEN J. Parenter. Enter. Nutr. 1988;12:20–24. doi: 10.1177/014860718801200120. PubMed DOI

Elia M., Ritz P., Stubbs R.J. Total energy expenditure in the elderly. Eur. J. Clin. Nutr. 2000;54:S92–S103. doi: 10.1038/sj.ejcn.1601030. PubMed DOI

Matthews D.E., Pesola G., Campbell R.G. Effect of epinephrine on amino acid and energy metabolism in humans. Am. J. Physiol. 1990;258:E948–E956. doi: 10.1152/ajpendo.1990.258.6.E948. PubMed DOI

Bessey P.Q., Watters J.M., Aoki T.T., Wilmore D.W. Combined hormonal infusion simulates the metabolic response to injury. Ann. Surg. 1984;200:264–281. doi: 10.1097/00000658-198409000-00004. PubMed DOI PMC

Ratheiser K.M., Brillon D.J., Campbell R.G., Matthews D.E. Epinephrine produces a prolonged elevation in metabolic rate in humans. Am. J. Clin. Nutr. 1998;68:1046–1052. doi: 10.1093/ajcn/68.5.1046. PubMed DOI

Wolfe R.R., Shaw J.H. Effect of epinephrine infusion and adrenergic blockade on glucose oxidation in conscious dogs. Metab. Clin. Exp. 1986;35:673–678. doi: 10.1016/0026-0495(86)90177-0. PubMed DOI

Ensinger H., Weichel T., Lindner K.H., Grunert A., Ahnefeld F.W. Effects of norepinephrine, epinephrine, and dopamine infusions on oxygen consumption in volunteers. Crit. Care Med. 1993;21:1502–1508. doi: 10.1097/00003246-199310000-00018. PubMed DOI

Watt M.J., Howlett K.F., Febbraio M.A., Spriet L.L., Hargreaves M. Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans. J. Physiol. 2001;534:269–278. doi: 10.1111/j.1469-7793.2001.t01-1-00269.x. PubMed DOI PMC

Hoeks J., van Baak M.A., Hesselink M.K., Hul G.B., Vidal H., Saris W.H., Schrauwen P. Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am. J. Physiology. Endocrinol. Metab. 2003;285:E775–E782. doi: 10.1152/ajpendo.00175.2003. PubMed DOI

Jones C.T., Ritchie J.W. The metabolic and endocrine effects of circulating catecholamines in fetal sheep. J. Physiol. 1978;285:395–408. doi: 10.1113/jphysiol.1978.sp012578. PubMed DOI PMC

Ensinger H., Geisser W., Brinkmann A., Wachter U., Vogt J., Radermacher P., Georgieff M., Trager K. Metabolic effects of norepinephrine and dobutamine in healthy volunteers. Shock. 2002;18:495–500. doi: 10.1097/00024382-200212000-00002. PubMed DOI

Carpentier A.C., Blondin D.P., Virtanen K.A., Richard D., Haman F., Turcotte E.E. Brown Adipose Tissue Energy Metabolism in Humans. Front. Endocrinol. 2018;9:447. doi: 10.3389/fendo.2018.00447. PubMed DOI PMC

Heeren J., Scheja L. Brown adipose tissue and lipid metabolism. Curr. Opin. Lipidol. 2018;29:180–185. doi: 10.1097/MOL.0000000000000504. PubMed DOI

Sondergaard E., Gormsen L.C., Christensen M.H., Pedersen S.B., Christiansen P., Nielsen S., Poulsen P.L., Jessen N. Chronic adrenergic stimulation induces brown adipose tissue differentiation in visceral adipose tissue. Diabet Med. 2015;32:e4–e8. doi: 10.1111/dme.12595. PubMed DOI

Wang Q., Zhang M., Ning G., Gu W., Su T., Xu M., Li B., Wang W. Brown adipose tissue in humans is activated by elevated plasma catecholamines levels and is inversely related to central obesity. PLoS ONE. 2011;6:e21006. doi: 10.1371/journal.pone.0021006. PubMed DOI PMC

Fishbein L., Leshchiner I., Walter V., Danilova L., Robertson A.G., Johnson A.R., Lichtenberg T.M., Murray B.A., Ghayee H.K., Else T., et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31:181–193. doi: 10.1016/j.ccell.2017.01.001. PubMed DOI PMC

Tella S.H., Taieb D., Pacak K. HIF-2alpha: Achilles’ heel of pseudohypoxic subtype paraganglioma and other related conditions. Eur. J. Cancer. 2017;86:1–4. doi: 10.1016/j.ejca.2017.08.023. PubMed DOI PMC

Kluckova K., Tennant D.A. Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma. Cell Tissue Res. 2018;372:367–378. doi: 10.1007/s00441-018-2801-6. PubMed DOI PMC

Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. doi: 10.1126/science.123.3191.309. PubMed DOI

Taieb D., Pacak K. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Trends Endocrinol. Metab. 2017;28:807–817. doi: 10.1016/j.tem.2017.08.001. PubMed DOI PMC

van Berkel A., Rao J.U., Kusters B., Demir T., Visser E., Mensenkamp A.R., van der Laak J.A., Oosterwijk E., Lenders J.W., Sweep F.C., et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J. Nucl. Med. 2014;55:1253–1259. doi: 10.2967/jnumed.114.137034. PubMed DOI

Hayashi Y., Yokota A., Harada H., Huang G. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1alpha in cancer. Cancer Sci. 2019;110:1510–1517. doi: 10.1111/cas.13990. PubMed DOI PMC

Diamanti-Kandarakis E., Zapanti E., Peridis M.H., Ntavos P., Mastorakos G. Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Hormones. 2003;2:61–66. doi: 10.14310/horm.2002.1184. PubMed DOI